Loading stock data…
Teva Pharmaceutical Industries (TEVA)
$33.21-0.41 (-1.22%)
Market ClosedLast close Jun 26
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Teva Pharmaceutical Industries Limited in the Healthcare sector is trading at $33.21 with a market capitalization of $38.2B. Wall Street consensus targets $40.90 (10 analysts), implying a +23.2% move over the next 12 months. The stock is currently near its 52-week high of $37.35, remaining 14.1% above its 200-day moving average. On fundamentals, Piotroski 9/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.98B↓ | $4.71B↑ | $4.48B↑ | $4.18B↑ | $3.89B |
| Gross Profit | $1.97B↓ | $2.66B↑ | $2.30B↑ | $2.10B↑ | $1.88B |
| Operating Income | $759.00M↓ | $1.27B↑ | $1.07B↑ | $899.00M↑ | $706.00M |
| Net Income | $369.00M↓ | $480.00M↑ | $433.00M↑ | $282.00M↑ | $214.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.01%
Volume
Today's trading volume
4.70M
Recent News
Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best weight loss drugs on this list. TheFly reported on June 8 that TEVA announced new clinical and real-world findings supporting the use of Austedo and Austedo XR in patients with […]
Teva Pharmaceutical Industries (TEVA) Stock After 94% One-Year Surge Is The Price Justified
If you are wondering whether Teva Pharmaceutical Industries at US$33.21 is offering fair value or not, the next sections will walk through what the current share price may be implying. The stock has returned 0.9% over the past week, is down 2.5% over the last month, and shows returns of 7.3% year to date and 94.3% over the past year, with very large gains over three and five years. Recent attention on Teva Pharmaceutical Industries has centered on its position in the global generics and...
Is Ecopipam’s FDA Filing Reshaping the Investment Case For Teva Pharmaceutical Industries (TEVA)?
Earlier in June, Teva Pharmaceutical Industries submitted a New Drug Application to the U.S. FDA for ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome, supported by positive Phase 3 data published in JAMA Neurology and backed by Orphan Drug and Fast Track designations. If approved, ecopipam could become the first new FDA-approved treatment for pediatric Tourette syndrome in more than a decade, underscoring Teva’s push to expand its...
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth
TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.